# Mettler Toledo International Inc/: Form 10-Q for the period ended Mar 31, 2019

- Company: [Mettler Toledo International Inc/](/companies/mtd.md) (CIK 1037646)
- Form: 10-Q
- Filed: 2019-05-10
- Accepted by EDGAR: May 10, 2019, 12:19 ET
- Period: 2019-03-31
- Accession: 0001037646-19-000020
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/1037646/000103764619000020/mtd_10qx3312019.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/1037646/000103764619000020/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2019-03-31.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Revenue | 3 months, 2019-01-01 to 2019-03-31 | $679.5m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Gross profit | 3 months, 2019-01-01 to 2019-03-31 | $388.3m | us-gaap:GrossProfit |
| Research and development | 3 months, 2019-01-01 to 2019-03-31 | $36.1m | us-gaap:ResearchAndDevelopmentExpense |
| Selling, general and administrative | 3 months, 2019-01-01 to 2019-03-31 | $204.4m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Interest expense | 3 months, 2019-01-01 to 2019-03-31 | $9.1m | us-gaap:InterestExpense |
| Income tax | 3 months, 2019-01-01 to 2019-03-31 | $13.9m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months, 2019-01-01 to 2019-03-31 | $111.8m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months, 2019-01-01 to 2019-03-31 | $4.42 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months, 2019-01-01 to 2019-03-31 | $4.50 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months, 2019-01-01 to 2019-03-31 | 25,310,525 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 3 months, 2019-01-01 to 2019-03-31 | $98.8m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 3 months, 2019-01-01 to 2019-03-31 | $22.4m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Share repurchases | 3 months, 2019-01-01 to 2019-03-31 | $186.3m | us-gaap:PaymentsForRepurchaseOfCommonStock |
| Cash and equivalents | at 2019-03-31 | $126.5m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | at 2019-03-31 | $969.4m | us-gaap:AssetsCurrent |
| Total assets | at 2019-03-31 | $2.64bn | us-gaap:Assets |
| Current liabilities | at 2019-03-31 | $708.0m | us-gaap:LiabilitiesCurrent |
| Total liabilities | at 2019-03-31 | $2.07bn | us-gaap:Liabilities |
| Long-term debt | at 2019-03-31 | $1.01bn | us-gaap:LongTermDebtNoncurrent |
| Shareholders' equity | at 2019-03-31 | $561.8m | us-gaap:StockholdersEquity |
| Shares outstanding | at 2019-03-31 | 24,803,286 shares | dei:EntityCommonStockSharesOutstanding |

## Management's discussion and analysis

As filed, 26,024 characters.

*The following discussion and analysis of our financial condition and results of operations should be read in conjunction with the Unaudited Interim Consolidated Financial Statements included herein.*

### General

Our interim consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America. Operating results for the three months ended March 31, 2019 are not necessarily indicative of the results to be expected for the full year ending December 31, 2019.

Changes in local currencies exclude the effect of currency exchange rate fluctuations. Local currency amounts are determined by translating current and previous year consolidated financial information at an index utilizing historical currency exchange rates. We believe local currency information provides a helpful assessment of business performance and a useful measure of results between periods. We do not, nor do we suggest that investors should, consider such non-GAAP financial measures in isolation from, or as a substitute for, financial information prepared in accordance with GAAP. We present non-GAAP financial measures in reporting our financial results to provide investors with an additional analytical tool to evaluate our operating results.

We also include in the discussion below disclosures of immaterial qualitative factors that are not quantified. Although the impact of such factors is not considered material, we believe these disclosures can be useful in evaluating our operating results.

### Results of Operations – Consolidated

The following tables set forth items from our interim consolidated statements of operations and comprehensive income for the three month periods ended March 31, 2019 and 2018 (amounts in thousands).

|  | Three months ended March 31, 2019 (unaudited)% |  | 2018 (unaudited)% |  |
| --- | ---: | ---: | ---: | ---: |
| Net sales | $679,452 | 100.0 | $660,821 | 100.0 |
| Cost of sales | 291,133 | 42.8 | 285,888 | 43.3 |
| Gross profit | 388,319 | 57.2 | 374,933 | 56.7 |
| Research and development | 36,053 | 5.3 | 34,713 | 5.3 |
| Selling, general and administrative | 204,425 | 30.1 | 200,674 | 30.4 |
| Amortization | 12,222 | 1.8 | 11,735 | 1.8 |
| Interest expense | 9,094 | 1.3 | 8,359 | 1.3 |
| Restructuring charges | 1,523 | 0.2 | 4,413 | 0.6 |
| Other charges (income), net | (674) | — | (2,400) | (0.4) |
| Earnings before taxes | 125,676 | 18.5 | 117,439 | 17.8 |
| Provision for taxes | 13,871 | 2.0 | 24,135 | 3.7 |
| Net earnings | $111,805 | 16.5 | $93,304 | 14.1 |

#### Net sales

Net sales were $679.5 million for the three months ended March 31, 2019, compared to $660.8 million for the corresponding period in 2018. This represents an increase in U.S. dollars of 3%. Excluding the effect of currency exchange rate fluctuations, or in local currencies, net sales increased 7% for the three months ended March 31, 2019. Global market conditions were generally favorable during the first quarter of 2019. We also continue to benefit from the execution of our global sales and marketing programs, our innovative product portfolio, and investments in our field resources. However, we remain cautious as economic uncertainties exist in certain regions of the world. Economic conditions can also change quickly, particularly in emerging markets.

Net sales by geographic destination for the three months ended March 31, 2019 in U.S. dollars increased 3% in the Americas, 2% in Europe and 4% in Asia/Rest of World. In local currencies, our net sales by geographic destination increased 3% in the Americas, 9% in Europe and 9% in Asia/Rest of World. Net sales in the Americas was reduced 3% related to a significant decline in food retailing primarily due to the timing of project activity. A discussion of sales by operating segment is included below.

As described in Note 17 to our consolidated financial statements for the year ended December 31, 2018, our net sales comprise product sales of precision instruments and related services. Service revenues are primarily derived from repair and other services, including regulatory compliance qualification, calibration, certification, preventative maintenance and spare parts.

Net sales of products increased 3% in U.S. dollars and 7% in local currency for the three months ended March 31, 2019 compared to the prior period. Service revenue (including spare parts) increased 3% in U.S. dollars and 8% in local currency during the three months ended March 31, 2019 compared to the corresponding period in 2018.

Net sales of our laboratory products and services, which represented approximately 53% of our total net sales for the three months ended March 31, 2019, increased 4% in U.S. dollars and 8% in local currencies during the three months ended March 31, 2019. The local currency increase in net sales of our laboratory-related products includes strong growth in most product categories, especially process analytics, analytical instruments and pipettes.

Net sales of our industrial products and services, which represented approximately 40% of our total net sales for the three months ended March 31, 2019, increased 3% in U.S. dollars and 8% in local currencies during the three months ended March 31, 2019. The local currency increase in net sales of our industrial-related products includes strong growth in core industrial, as well as solid growth in product inspection.

Net sales in our food retailing products and services, which represented approximately 7% of our total net sales for the three months ended March 31, 2019, decreased 9% in U.S. dollars and 5% in local currencies during the three months ended March 31, 2019. Food retailing sales declined significantly in the Americas primarily due to timing of project activity, partially offset by increases in Europe and Asia/Rest of World.

#### Gross profit

Gross profit as a percentage of net sales was 57.2% for the three months ended March 31, 2019 compared to 56.7% for the corresponding period in 2018.

Gross profit as a percentage of net sales for products was 59.9% and 60.4% for the three month periods ended March 31, 2019 and 2018.

Gross profit as a percentage of net sales for services (including spare parts) was 47.8% for the three months ended March 31, 2019 compared to 44.4% for the corresponding period in 2018.

The increase in gross profit as a percentage of net sales for the three months ended March 31, 2019 reflects favorable price realization and productivity, partially offset by tariff costs and initial costs associated with new product introductions.

In 2018, the U.S. government enacted tariffs on certain products imported from China. The tariffs became effective at various points during 2018. We estimate the associated annualized cost increase is approximately $25 million (assuming a 25% tariff rate). We continue to evaluate and implement various actions to mitigate the effects of these tariffs.

#### Research and development and selling, general and administrative expenses

Research and development expenses as a percentage of net sales was 5.3% for both the three months ended March 31, 2019 and 2018, respectively. Research and development expenses increased 4% in U.S. dollars and 9% in local currencies, during the three months ended March 31, 2019 compared to the corresponding period in 2018 relating to increased research and development project activity.

Selling, general and administrative expenses as a percentage of net sales were 30.1% for the three months ended March 31, 2019 compared to 30.4% in the corresponding period during 2018. Selling, general and administrative expenses increased 2% in U.S. dollars and 6% in local currencies, during the three months ended March 31, 2019 compared to the corresponding period in 2018. The local currency increase includes investments in our field sales organization and growth initiatives and higher cash incentive expense, offset in part by benefits from our cost savings initiatives.

#### Amortization, interest expense, other charges (income), net and taxes

Amortization expense was $12.2 million for the three months ended March 31, 2019 and $11.7 million for the corresponding period in 2018.

Interest expense was $9.1 million for the three months ended March 31, 2019 and $8.4 million for the corresponding period in 2018.

Other charges (income), net includes non-service pension costs (benefits), (gains) losses from foreign currency transactions and related hedging activities, interest income and other items. Non-service pension benefits for the three months ended March 31, 2019 and 2018 were $1.2 million and $1.6 million, respectively.

Our reported tax rate was 11% and 21% during the three months ended March 31, 2019 and 2018, respectively. The provision for taxes is based upon using our projected annual effective tax rate of 20.5% and 22% before non-recurring discrete tax items for the three months ended March 31, 2019 and 2018, respectively. The difference between our projected annual effective tax rate and the reported tax rate is related to the timing of excess tax benefits associated with stock option exercises.

### Results of Operations – by Operating Segment

The following is a discussion of the financial results of our operating segments. We currently have five reportable segments: U.S. Operations, Swiss Operations, Western European Operations, Chinese Operations and Other. A more detailed description of these segments is outlined in Note 17 to our consolidated financial statements for the year ended December 31, 2018.

#### U.S. Operations (amounts in thousands)

|  | Three months ended March 31, |  |
| --- | ---: | ---: |
|  | 2019 | 2018% |
| Total net sales | $260,795 | $253,411 3% |
| Net sales to external customers | $234,650 | $229,745 2% |
| Segment profit | $37,985 | $34,245 11% |

Total net sales and net sales to external customers increased 3% and 2%, respectively for the three months ended March 31, 2019 compared with the corresponding period in 2018. The increase in total net sales and net sales to external customers includes strong growth in laboratory-related products, partially offset by a significant decline in food retailing primarily due to the timing of project activity which reduced net sales by 3%.

Segment profit increased $3.7 million for the three months ended March 31, 2019 compared to the corresponding period in 2018 and included benefits from our margin expansion and facility consolidation initiatives, offset in part by investments in our sales and service organization and initial costs of new product introductions.

#### Swiss Operations (amounts in thousands)

|  | Three months ended March 31, 2019 | 2018 | %1) |
| --- | ---: | ---: | ---: |
| Total net sales | $187,308 | $176,048 | 6% |
| Net sales to external customers | $33,577 | $32,466 | 3% |
| Segment profit | $53,522 | $45,975 | 16% |

1\) Represents U.S. dollar (decline) growth for net sales and segment profit.

Total net sales increased 6% in U.S. dollars and 12% in local currency for the three months ended March 31, 2019 compared to the corresponding period in 2018. Net sales to external customers increased 3% in U.S. dollars and 7% in local currency during the three months ended March 31, 2019 compared to the corresponding period in 2018. The increase in local currency net sales to external customers for the three month period ended March 31, 2019 includes strong growth in most product categories.

Segment profit increased $7.5 million for the three month period ended March 31, 2019 compared to the corresponding period in 2018. Segment profit during the three months ended March 31, 2019 includes the benefit of increased net sales volume and our margin expansion initiatives, offset in part by unfavorable foreign currency translation.

#### Western European Operations (amounts in thousands)

|  | Three months ended March 31, 2019 | 2018 | %1) |
| --- | ---: | ---: | ---: |
| Total net sales | $209,951 | $206,384 | 2% |
| Net sales to external customers | $165,906 | $165,372 | 0% |
| Segment profit | $25,725 | $18,282 | 41% |

1\) Represents U.S. dollar (decline) growth for net sales and segment profit.

Total net sales increased 2% in U.S. dollars and increased 10% in local currencies during the three month period ended March 31, 2019 compared to the corresponding period in 2018. Net sales to external customers were flat in U.S. dollars and increased 9% in local currencies during the three month period ended March 31, 2019 compared to the corresponding period in 2018. The local currency increase in net sales to external customers for the three months ended March 31, 2019 includes strong growth in most product categories, with particularly strong growth in core industrial, laboratory balances, process analytics and analytical instruments.

Segment profit increased $7.4 million for the three month period ended March 31, 2019 compared to the corresponding period in 2018. The increase in segment profit includes an increase in sales volume, prior year Blue Ocean roll-in costs, and benefits from our margin expansion initiatives, offset in part by investments in our sales and service organization and unfavorable foreign currency translation.

#### Chinese Operations (amounts in thousands)

|  | Three months ended March 31, 2019 | 2018 | %1) |
| --- | ---: | ---: | ---: |
| Total net sales | $178,580 | $174,337 | 2% |
| Net sales to external customers | $121,723 | $113,930 | 7% |
| Segment profit | $59,484 | $59,553 | —% |

1\) Represents U.S. dollar (decline) growth for net sales and segment profit.

Total net sales increased 2% in U.S. dollars and 8% in local currency for the three months ended March 31, 2019 compared to the corresponding period in 2018. Net sales to external customers increased 7% in U.S. dollars and 13% in local currency during the three months ended March 31, 2019 compared to the corresponding period in 2018. The increase in local currency net sales to external customers during the three months ended March 31, 2019 reflects strong growth in both laboratory and industrial products. While Chinese market conditions are currently favorable, the Chinese economy has historically been volatile and market conditions may change unfavorably due to various factors.

Segment profit decreased $0.1 million for the three month period ended March 31, 2019 compared to the corresponding period in 2018. The decrease in segment profit for the three month period ended March 31, 2019 includes increased sales and service investments, unfavorable foreign currency translation, and higher research and development activity, offset by increased sales volume and benefits from our margin expansion initiatives.

#### Other (amounts in thousands)

|  | Three months ended March 31, 2019 | 2018 | %1) |
| --- | ---: | ---: | ---: |
| Total net sales | $124,857 | $120,948 | 3% |
| Net sales to external customers | $123,596 | $119,308 | 4% |
| Segment profit | $13,187 | $13,881 | (5)% |

1\) Represents U.S. dollar (decline) growth for net sales and segment profit.

Total net sales and net sales to external customers increased 3% and 4% respectively, in U.S. dollars and both increased 8% in local currencies during the three month period ended March 31, 2019 compared to the corresponding period in 2018. Local currency growth in was driven by strong growth in most product categories.

Segment profit decreased $0.7 for the three months ended March 31, 2019 compared to the corresponding period in 2018. The decrease in segment profit is primarily related to unfavorable foreign currency translation, offset in part by increased local currency net sales.

### Liquidity and Capital Resources

Liquidity is our ability to generate sufficient cash flows from operating activities to meet our obligations and commitments. In addition, liquidity includes the ability to obtain appropriate financing. Currently, our financing requirements are primarily driven by working capital requirements, capital expenditures, share repurchases and acquisitions.

Cash provided by operating activities totaled $98.8 million during the three months ended March 31, 2019, compared to $76.6 million in the corresponding period in 2018. The increase in 2019 includes higher net earnings and a lower working capital outflow, which includes lower cash incentive payments of $18 million that was partly offset by working capital timing.

Capital expenditures are made primarily for investments in information systems and technology, machinery, equipment and the purchase and expansion of facilities. Our capital expenditures totaled $22.4 million for the three months ended March 31, 2019 compared to $29.8 million in the corresponding period in 2018. The decrease is primarily related to prior year investments in manufacturing facilities. We expect to make net investments in new or expanded manufacturing facilities of $10 million to $15 million over the next two years.

We recorded charges of $3.6 million and $72 million in 2018 and 2017, respectively, for the estimated income tax effects of the Transition Tax associated with the Tax Cuts and Jobs Act of which $62 million is expected to be paid over a period of up to eight years. We also plan to continue to repatriate earnings from China, Switzerland, Germany, the United Kingdom, and certain other countries in future years and expect the only additional cost associated with the repatriation of such foreign earnings will be withholding taxes. All other undistributed earnings are considered to be permanently reinvested. We believe the ongoing tax impact associated with repatriating our undistributed foreign earnings will not have a material effect on our liquidity.

#### Senior Notes and Credit Facility Agreement

Our debt consisted of the following at March 31, 2019:

|  | March 31, 2019 U.S. Dollar | Other Principal Trading Currencies | Total |
| --- | ---: | ---: | ---: |
| 3.67% $50 million Senior Notes due December 17, 2022 | $50,000 | $— | $50,000 |
| 4.10% $50 million Senior Notes due September 19, 2023 | 50,000 | — | 50,000 |
| 3.84% $125 million Senior Notes due September 19, 2024 | 125,000 | — | 125,000 |
| 4.24% $125 million Senior Notes due June 25, 2025 | 125,000 | — | 125,000 |
| 1.47% Euro 125 million Senior Notes due June 17, 2030 | — | 140,750 | 140,750 |
| Senior notes debt issuance costs, net | (862) | (321) | (1,183) |
| Total Senior Notes | 349,138 | 140,429 | 489,567 |
| $1.1 billion Credit Agreement, interest at LIBOR plus 87.5 basis points | 440,532 | 78,386 | 518,918 |
| Other local arrangements | 1,261 | 52,537 | 53,798 |
| Total debt | 790,931 | 271,352 | 1,062,283 |
| Less: current portion | (1,261) | (52,537) | (53,798) |
| Total long-term debt | $789,670 | $218,815 | $1,008,485 |

As of March 31, 2019, approximately $575.2 million was available under our Credit Agreement. Changes in exchange rates between the currencies in which we generate cash flows and the currencies in which our borrowings are denominated affect our liquidity. In addition, because we borrow in a variety of currencies, our debt balances fluctuate due to changes in exchange rates. Further, we do not have any downgrade triggers relating to ratings from rating agencies that would accelerate the maturity dates of our debt.

We currently believe that cash flow from operating activities, together with liquidity available under our Credit Agreement and local working capital facilities, will be sufficient to fund currently anticipated working capital needs and capital spending requirements for the foreseeable future.

In April 2019, the Company entered into an agreement to issue and sell $75 million of ten-year Senior Notes in a private placement. The Company will issue the Senior Notes with a fixed interest rate of 3.91% ("3.91% Senior Notes") in June 2019. The 3.91% Senior Notes are unsecured obligations of the Company and will mature in June 2029. Interest on the 3.91% Senior Notes is payable semi-annually in June and December of each year.

The 3.91% Senior Notes contain customary affirmative and negative covenants including, among others, limitations on the Company and its subsidiaries with respect to incurrence of liens and priority indebtedness, disposition of assets, mergers, and transactions with affiliates. The note purchase agreement also requires the Company to maintain a consolidated interest coverage ratio of more than 3.5 to 1.0 and a consolidated leverage ratio of less than 3.5 to 1.0. The agreement contains customary events of defaults with customary grace periods, as applicable.

We continue to explore potential acquisitions. In connection with any acquisition, we may incur additional indebtedness. During the three months ended March 31, 2019, we paid $10 million related to the settlement of the Biotix acquisition contingent consideration as further described in Note 4 of our 2018 Consolidated Financial Statements.

In April 2018, two of our non-U.S. pension plans issued loans totaling $39.6 million (Swiss franc 38 million) to our wholly owned subsidiary. The loans have the same terms and conditions which include an interest rate of Swiss franc LIBOR plus 87.5 basis points and a maturity date of April 2019 and a one year renewal term and, as such, are classified as short-term debt on our

consolidated balance sheet. The proceeds were used to repay outstanding amounts on our credit facility.

#### Share Repurchase Program

In November 2018, the Company's Board of Directors authorized an additional $2.0 billion to the share repurchase program which has $1.9 billion of remaining availability as of March 31, 2019. The share repurchases are expected to be funded from cash generated from operating activities, borrowings, and cash balances. Repurchases will be made through open market transactions, and the amount and timing of purchases will depend on business and market conditions, the stock price, trading restrictions, the level of acquisition activity, and other factors.

We have purchased 27.8 million common shares since the inception of the program in 2004 through March 31, 2019. During both the three months ended March 31, 2019 and 2018, we spent $186.3 million and $118.8 million on the repurchase of 290,429 shares and 187,880 shares at an average price per share of $641.27 and $632.03, respectively. We reissued 171,752 shares and 39,362 shares held in treasury for the exercise of stock options and restricted stock units during the three months ended March 31, 2019 and 2018, respectively.

### Effect of Currency on Results of Operations

Our earnings are affected by changing exchange rates. We are most sensitive to changes in the exchange rates between the Swiss franc, euro, and U.S. dollar. We have more Swiss franc expenses than we do Swiss franc sales because we develop and manufacture products in Switzerland that we sell globally, and have a number of corporate functions located in Switzerland. When the Swiss franc strengthens against our other trading currencies, particularly the U.S. dollar and euro, our earnings go down. We also have significantly more sales in the euro than we do expenses. When the euro weakens against the U.S. dollar and Swiss franc, our earnings also go down. We estimate a 1% strengthening of the Swiss franc against the euro would reduce our earnings before tax by approximately $1.6 million to $1.8 million annually.

We also conduct business in many geographies throughout the world, including Asia Pacific, the United Kingdom, Eastern Europe, Latin America, and Canada. Fluctuations in these currency exchange rates against the U.S. dollar can also affect our operating results. The most significant of these currency exposures is the Chinese Renminbi. The impact on our earnings before tax of the Chinese Renminbi weakening 1% against the U.S. dollar is a reduction of approximately $1.5 million to $1.7 million annually.

In addition to the effects of exchange rate movements on operating profits, our debt levels can fluctuate due to changes in exchange rates, particularly between the U.S. dollar and the Swiss franc. Based on our outstanding debt at March 31, 2019, we estimate that a 10% weakening of the U.S. dollar against the currencies in which our debt is denominated would result in an increase of approximately $30.2 million in the reported U.S. dollar value of our debt.

### Forward-Looking Statements Disclaimer

*You should not rely on forward-looking statements to predict our actual results. Our actual results or performance may be materially different than reflected in forward-looking statements because of various risks and uncertainties. You can identify forward-looking statements by terminology such as “may,” “will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,” “predict,” “potential” or “continue”.*

*We make forward-looking statements about future events or our future financial performance, including earnings and sales growth, earnings per share, strategic plans and contingency plans, growth opportunities or economic downturns, our ability to respond to changes in market conditions, planned research and development efforts and product introductions, adequacy of facilities, access to and the costs of raw materials, shipping and supplier costs, gross margins, customer demand, our competitive position , capital expenditures, cash flow, tax-related matters, compliance with laws, and effects of acquisitions.*

*Our forward-looking statements may not be accurate or complete, and we do not intend to update or revise them in light of actual results. New risks also periodically arise. Please consider the risks and factors that could cause our results to differ materially from what is described in our forward-looking statements. See in particular “Factors Affecting Our Future Operating Results” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” of our 2018 Annual Report on Form 10-K.*

## Market risk

As filed, 174 characters.

As of March 31, 2019, there was no material change in the information provided under Item 7A in the Company’s Annual Report on Form 10-K for the year ended December 31, 2018.

## Controls and procedures

As filed, 1,523 characters.

Under the supervision and with the participation of our management, including the Chief Executive Officer and Chief Financial Officer we have evaluated the effectiveness of our disclosure controls and procedures as required by Exchange Act Rule 13a-15(b) as of the end of the period covered by this report. Based upon that evaluation, the Chief Executive Officer and Chief Financial Officer have concluded that these disclosure controls and procedures are effective. There were no changes in our internal control over financial reporting during the quarter ended March 31, 2019 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

We adopted ASC 842 "Leases" on January 1, 2019. As a result of adopting this new accounting standard we have modified processes and controls included in our framework of internal controls over financial reporting (ICFR). Management has implemented an additional system, processes, and controls that were designed and operating effectively as part of the implementation process. Such additional system, processes and controls include but are not limited to (i) the development, review and approval of certain management judgments and estimates in evaluating contract terms, (ii) evaluating the significant inputs subject to the determination of completeness and accuracy of the lease liability and the related lease right-of-use asset, and (iii) the ongoing accounting and financial reporting in accordance with ASC 842.

## Risk factors

As filed, 201 characters.

For the three months ended March 31, 2019 there were no material changes from risk factors disclosed in Part I, Item 1A of the Company’s Annual Report on Form 10-K for the year ended December 31, 2018.

Filed May 10, 2019.
Source: SEC EDGAR, the filing index for accession 0001037646-19-000020. Last ingested by Listed: Nov 13, 2026, 02:43 ET. No prices; not investment advice.
